Mateon Therapeutics
Sep 6, 2017

Mateon Therapeutics to Present at the 19th Annual Rodman and Renshaw Global Investment Conference on September 12, 2017

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents for the treatment of orphan oncology indications, today announced it will be featured as a presenting company at the 19th Annual Rodman & Renshaw Global Investment Conference. Mateon's presentation will take place on Tuesday, September 12, 2017 at 3:00 p.m. eastern time at the Lotte New York Palace Hotel in New York.

To listen to a live webcast of the presentation, please visit the Company's website, www.mateon.com. Under the "Investors & News" tab, select the link to "Events & Presentations." A replay of the webcast will be available at this same location for a period of time following the conclusion of the live event.

About Mateon
Mateon Therapeutics, Inc. is a biopharmaceutical company seeking to realize the full potential of vascular targeted therapy (VTT) in oncology. VTT includes vascular disrupting agents (VDAs) such as the investigational drugs that Mateon is developing, and anti-angiogenic agents (AAs), a number of which are FDA-approved and widely used in cancer treatment. These two approaches have distinct yet complementary mechanisms of action.

At Mateon, we believe that we can significantly improve cancer therapy by employing these two complementary approaches simultaneously. When utilized this way, VDAs obstruct existing blood vessels in the tumor leading to significant central tumor cell death while AAs prevent the formation of new tumor blood vessels.

Mateon is committed to leveraging our intellectual property and the product development expertise of our highly skilled management team to enable VTT to realize its true potential and to bring much-needed new therapies to cancer patients worldwide. 


CONTACTS 



Investors:

Mateon Therapeutics, Inc.

Matthew M. Loar

ir@mateon.com

650-635-7000



Media:

JPA Health Communications

Nic DiBella

nic@jpa.com

617-945-5183

Primary Logo

Source: Mateon Therapeutics

News Provided by Acquire Media